Literature DB >> 18418231

Homocysteine predicts adverse clinical outcomes in unstable angina and non-ST elevation myocardial infarction: implications from the folate intervention in non-ST elevation myocardial infarction and unstable angina study.

Jose B Nevado1, Marcelo Severino B Imasa.   

Abstract

BACKGROUND: Unstable angina and non-ST elevation myocardial infarction (NSTEMI) are common acute coronary events. Homocysteine is a novel risk factor for coronary heart diseases. Together with the conventional risk factors, they may affect the outcome of non-ST coronary events.
OBJECTIVE: This study aims to determine the effect of clinical risk factors that are responsible for the occurrence of mortality, and the composite outcome of mortality, nonfatal myocardial infarction and serious rehospitalization within 6 months after the onset of non-ST acute coronary syndromes.
METHODS: A total of 124 Filipino patients were interviewed and tested for blood homocysteine levels and lipid profiles. Outcomes were assessed after 6 months.
RESULTS: Homocysteinemia (>16 micromol/l) is associated with increased mortality and composite outcomes (mortality, nonfatal reinfarction, and serious rehospitalization), even if adjusted for conventional risk factors. No association was detected for the conventional risk factors. Earlier acute coronary syndrome was found to be positively associated with mortality and the composite outcomes. Early stroke is associated with increased composite outcomes, whereas greater mortality and adverse outcomes were observed in NSTEMI compared with intermediate-risk unstable angina.
CONCLUSION: Increased homocysteine level is associated with mortality and serious nonfatal outcomes in patients with unstable angina and NSTEMI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18418231     DOI: 10.1097/MCA.0b013e3282f52910

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  3 in total

Review 1.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

2.  Homocysteine and long-term recurrent infarction following an acute coronary syndrome.

Authors:  Gema Miñana; Carolina Gil-Cayuela; Lorenzo Fácila; Vicent Bodi; Ernesto Valero; Anna Mollar; Maria Marco; Teresa García-Ballester; Begoña Zorio; Jorge Martí-Cervera; Eduardo Núñez; Francisco J Chorro; Juan Sanchis; Julio Núñez
Journal:  Cardiol J       Date:  2020-12-21       Impact factor: 2.737

Review 3.  Homocysteine-lowering interventions for preventing cardiovascular events.

Authors:  Arturo J Martí-Carvajal; Ivan Solà; Dimitrios Lathyris; Mark Dayer
Journal:  Cochrane Database Syst Rev       Date:  2017-08-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.